ArticleAmerican journal of translational research2026
A multiparameter model combining ultrasound and maternal serum biomarkers accurately predicts late-onset fetal growth restriction.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLate-onset fetal growth restriction (FGR) in pregnancy is frequently encountered and is linked to adverse perinatal results. This investigation aimed to evaluate the clinical use of a multiparameter model combining ultrasound features and maternal serum biomarkers for late-onset FGR.
methodsA retrospective investigation was conducted on 350 pregnant women in their third trimester who received standard prenatal care between January 2021 and December 2025. Participants were divided into a late-onset FGR group (n = 175) and a normal fetal development group (n = 175) according to the Chinese expert consensus criteria. Ultrasound findings including fetal biometry and Doppler flow indices were measured. Maternal serum levels of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PLGF) were quantified through enzyme-linked immunosorbent assay. Subsequently, the sFlt-1 to PLGF ratio (sFlt-1/PLGF) was calculated.
resultsAmong the 350 enrolled women, the FGR group exhibited markedly reduced abdominal circumference, estimated fetal weight, cerebroplacental ratio, and elevated uterine artery-pulsatility index and sFlt-1/PLGF compared to those in the normal group (all P < 0.05). The multiparameter evaluation model achieved an area under the curve of 0.977, demonstrating a sensitivity of 91.4% and specificity of 92.6% at the optimal threshold.
conclusionsThe multiparameter model integrating ultrasound features and maternal serum biomarkers demonstrated excellent predictive performance for late-onset FGR, supporting its clinical use for early identification and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.